Rociletinib hydrobromide is an orally delivered inhibitor of the mutant form of EGFR kinase (Kis: 21.5 nM and 303.3 nM for EGFR L858R/T790M and EGFR WT).

STAT3-IN-20（Compound 40）是一种选择性地靶向STAT3的SH2结构域，展现了在DU145和MDA-MB-231癌细胞中的抗增殖效果（IC50分别为2.97 μM和3.26 μM），并诱导细胞周期停滞与细胞凋亡。该抑制剂有效抑制了STAT3的磷酸化、核内易位及其下游基因的转录活性（IC50: 0.65 μM）。

STAT3-IN-23 (PY*LKTK) 为一种高效STAT3抑制剂。

Uzansertib (INCB053914) is a potent ATP-competitive pan-PIM kinase inhibitor. It exhibits exceptional inhibitory activity against PIM1, PIM2, and PIM3 with IC50 values of 0.24 nM, 30 nM, and 0.12 nM, respectively. Furthermore, Uzansertib demonstrates significant anti-proliferative effects against an assorted range of hematologic tumor cell lines.

MS9427 是一种有效的PROTACEGFR 降解剂，对野生型EGFR 和突变型EGFRL858R 的Kd 分别为 7.1 nM 和 4.3 nM。MS9427 通过泛素/蛋白酶体系统 (UPS) 和自噬/溶酶体途径选择性地降解突变体，但不降解WTEGFR。MS9427 对 NSCLC 细胞增殖有较强的抑制作用。MS9427 可用于抗癌研究。

HDS 029 在生命科学相关研究中具有广泛的应用。

Tetramethylcurcumin 是一种新型姜黄素类似物，是一种有效的 STAT3 磷酸化、DNA 结合活性和体外反式激活抑制剂。它具有抗炎和抗癌作用。

Protein Kinase Inhibitor 12 (compound 1-91) 是一种三唑比嗪的衍生物和蛋白激酶抑制剂，尤其对PIM-1、CDK-2、GSK-3和SRC哺乳动物蛋白激酶具有抑制效果，可用于研究与蛋白激酶相关的疾病。

Manassantin B is a potent inhibitor of NF-κB activation by the suppression of transciptional activity of RelA/p65 subunit of NF-κB. It also possesses anti-EBV lytic replication activity. Manassantin B inhibits interleukin-6-induced signal transducer and activator of transcription 3 activation in Hep3B cells, it has potential as a potent anti-inflammatory drug for use in pathological processes such as sepsis or acute lung injury. Manassantin B exerts antifibrotic activity in HSC-T6 cells, in part, via inhibition of cell proliferation and decrease of collagen production.